Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tofflon Science and Technology Group Co., Ltd. (300171.SZ)
Shanghai, CN
Tofflon Science and Technology Group Co., Ltd., originally established in 1993 as Shanghai Tofflon Science and Technology Co., Ltd. and headquartered in Shanghai, China, serves as a global purveyor of sophisticated equipment for the pharmaceutical and biotechnology sectors. The company's diverse offerings encompass specialized machinery for injectable drug manufacturing, including automated systems for solution preparation, aseptic filling lines tailored for ampoules, vials, syringes, and powders, along with freeze dryers featuring automatic loading capabilities, barrier systems, and plastic packaging machines. Beyond equipment, Tofflon also supplies active pharmaceutical ingredients and provides essential quality control systems such as visual inspection, leak detection, and integrated combination units. Furthermore, Tofflon is a significant provider of bio-process equipment and comprehensive integrated systems. These solutions cover various stages, from medium and buffer preparation to cell/microbial cultivation, harvesting, diafiltration/ultrafiltration (DF/UF), purification, and final filling processes. The company also offers specialized laboratory services for lyophilization of injectables.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.23% | -0.46% | -10.29% | -21.77% | -23.15% | -16.69% | +6.95% | -44.67% | -57.53% | -23.01% | +17.20% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+4.5% Q1'26: -2.5% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+0.0% Q1'26: +37.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+4.7% Q1'26: -6.2% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+6.2% Q1'26: +6.0% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+6.4% ★ Q1'26: +3.7% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+3.2% Q1'26: -0.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.18× ★ Q1'26: 0.27× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.56B
est: 1.53B (+1.5%)
|
1.33B
est: 1.48B (-10.2%)
|
1.72B
est: 1.54B (+12.1%)
|
1.92B
est: 1.89B (+1.4%)
|
2.26B
est: 2.09B (+8.1%)
|
2.71B
est: 2.77B (-2.4%)
|
4.19B
est: 4.16B (+0.8%)
|
5.47B
est: 5.47B (+0.1%)
|
5.64B
est: 5.92B (-4.6%)
|
5.01B
est: 4.99B (+0.5%)
|
5.23B
est: 5.27B (-0.7%)
|
5.91B
5.91B – 5.91B
+12.2% YoY
|
6.61B
6.61B – 6.61B
+11.8% YoY
|
| EBITDA |
385.50M
est: 231.16M (+66.8%)
|
251.46M
est: 222.84M (+12.8%)
|
192.07M
est: 231.92M (-17.2%)
|
95.15M
est: 285.04M (-66.6%)
|
195.47M
est: 315.74M (-38.1%)
|
512.09M
est: 418.09M (+22.5%)
|
980.91M
est: 627.06M (+56.4%)
|
926.16M
est: 823.97M (+12.4%)
|
678.01M
est: 891.97M (-24.0%)
|
206.67M
est: 654.21M (-68.4%)
|
477.11M
est: 691.41M (-31.0%)
|
775.77M
775.77M – 775.77M
+12.2% YoY
|
867.10M
867.10M – 867.10M
+11.8% YoY
|
| EBIT |
349.57M
est: 208.70M (+67.5%)
|
203.51M
est: 201.19M (+1.2%)
|
144.87M
est: 209.38M (-30.8%)
|
46.73M
est: 257.34M (-81.8%)
|
148.88M
est: 285.06M (-47.8%)
|
467.73M
est: 377.47M (+23.9%)
|
938.06M
est: 566.13M (+65.7%)
|
866.43M
est: 743.91M (+16.5%)
|
593.08M
est: 805.30M (-26.4%)
|
103.11M
est: 568.53M (-81.9%)
|
325.21M
est: 600.86M (-45.9%)
|
674.18M
674.18M – 674.18M
+12.2% YoY
|
753.55M
753.55M – 753.55M
+11.8% YoY
|
| Net Income |
386.69M
est: 601.06M (-35.7%)
|
234.51M
est: 295.92M (-20.8%)
|
123.10M
est: 210.05M (-41.4%)
|
70.46M
est: 79.49M (-11.4%)
|
145.81M
est: 70.24M (+107.6%)
|
463.49M
est: 574.81M (-19.4%)
|
827.78M
est: 985.40M (-16.0%)
|
846.57M
est: 843.56M (+0.4%)
|
600.24M
est: 768.91M (-21.9%)
|
194.09M
est: 323.69M (-40.0%)
|
200.38M
est: 246.62M (-18.7%)
|
377.63M
377.63M – 377.63M
+53.1% YoY
|
601.13M
601.13M – 601.13M
+59.2% YoY
|
| SGA |
296.28M
est: 227.88M (+30.0%)
|
314.75M
est: 219.68M (+43.3%)
|
310.42M
est: 228.63M (+35.8%)
|
393.29M
est: 281.00M (+40.0%)
|
416.33M
est: 311.27M (+33.8%)
|
421.48M
est: 412.17M (+2.3%)
|
565.32M
est: 618.18M (-8.6%)
|
723.74M
est: 812.30M (-10.9%)
|
868.82M
est: 879.33M (-1.2%)
|
833.46M
est: 755.69M (+10.3%)
|
890.32M
est: 798.66M (+11.5%)
|
896.12M
896.12M – 896.12M
+12.2% YoY
|
1.00B
1.00B – 1.00B
+11.8% YoY
|
| EPS |
0.62
est: 0.81 (-23.0%)
|
0.37
est: 0.40 (-6.7%)
|
0.20
est: 0.28 (-28.9%)
|
0.11
est: 0.11 (+5.3%)
|
0.23
est: 0.09 (+146.7%)
|
0.74
est: 0.77 (-3.9%)
|
1.32
est: 1.32 (+0.0%)
|
1.34
est: 1.13 (+18.6%)
|
0.79
est: 1.03 (-23.3%)
|
0.26
est: 0.42 (-38.1%)
|
0.26
est: 0.32 (-18.8%)
|
0.49
0.49 – 0.49
+53.1% YoY
|
0.78
0.78 – 0.78
+59.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 2/5 | 3/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.02% | 148.1K | 0.65% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 17.3K | 0.44% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 143.7K | 0.39% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 22.6K | 0.46% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 10.9K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 24.6K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.21M | 0.06% |
| 8 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 126.3K | 0.07% |
| 9 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 65.9K | 0.29% |
| 10 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 70.2K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dehua Lu | Financial Director | — | male |
| Hui Xing Tang | Deputy General Manager | — | male |
| Jin Wang Zheng | Technology Director & Director | — | male |
| Xiaodong Zheng | Chairman & GM | — | male |
| Yan Wang | Deputy GM & Secretary of the Board of Directors | — | female |
| Zhao Guo Xing | R & D Director | — | male |
| Zhao Wei | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300171.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
